Shun Lu
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
Shun Lu
Jun 26, 2024, 12:05 |
Insight
Piotr Wysocki: Osimertinib after radiochemotherapy improves PFS in EGFR-mutated NSCLC patients – but is it really what they need?
Piotr Wysocki recently posted on LinkedIn: "The results of the LAURA study were presented during a…
Jun 10, 2024, 00:53 |
Insight
Vijith Shetty: Osimertinib Could Alter SOC for Stage III EGFR+ NSCLC
Vijith Shetty, Associate Professor and Consultant Medical Oncologist at KS Hegde Medical Academy, shared on…
May 18, 2024, 09:06 |
Blog
Jarushka Naidoo: Perioperative Nivolumab in Stage IIA-IIIB NSCLC
Jarushka Naidoo shared on X/Twitter: ''Ph III CM77T trial at NEJM: Perioperative Nivolumab in Stage…
May 18, 2024, 08:33 |
Blog
Rami Manochakian: Results of Checkmate 77T trial of
Rami Manochakian shared a post on X/Twitter: ''Hot Off The Press. Just published at NEJM.…
All:
4
Posts:
1 - 10
Eliot Levitt: The Yvonne Awards demonstrate something that it doesn't hurt to be reminded of
New data from the NEST clinical trial was presented at ESMOGI24 - Agenus
Zainab Shinkafi-Bagudu's latest commentary on Cervical Cancer Elimination Forum
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Learn more about overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube